Literature DB >> 28389855

Management of rheumatoid arthritis in clinical practice using treat-to-target strategy: Where do we stand in the multi-ethnic Malaysia population?

Bee Eng Tan1, Ai Lee Lim2, Sow Lai Kan2, Chong Hong Lim2, Ying Fun Ng2, Serene Li Ching Tng3, Nur Syakirah Hassin3, Losshenee Chandran3, Norshahida Abdul Hamid3, Yvonne Yin Leng Lee4.   

Abstract

To evaluate the achievement of treat-to-target (T2T) strategy in rheumatoid arthritis (RA) and identify factors associated with failed treatment target in a public rheumatology center. A cross-sectional study was conducted from June 2015 to February 2016. RA patients with disease duration greater than 2 years and under T2T for over a year were invited to the study. Demographic, clinical data, disease activity score of 28 joints (DAS28), and clinical disease activity index (CDAI) were collected in a single routine clinic visit. Treatment target was defined as DAS28 <3.2 or CDAI ≤10. Retrospective chart review was performed to determine reasons of failed treatment target. A total of 371 patients were recruited and 87.1% were female. Mean age and duration of RA were 53.5 years (SD 10.3) and 9.1 years (SD 6.6), respectively. Ethnic distribution was 49% Chinese, 27% Malay, and 24% Indian. T2T was achieved in 81.7% of the cohort. Non-Chinese ethnicity, positive rheumatoid factor, and treatment with three disease modifying anti-rheumatic drugs (DMARDs) were associated with failed treatment target. After controlling for covariates, Malay ethnicity (OR 2.96; 95% CI 1.47-5.96) and treatment with three DMARDs (OR 2.14; 95% CI 1.06-4.35) were associated with failed treatment target. There was no association between age, gender, duration of RA, BMI, smoking status, anti-citrulinated cyclic peptide, and achievement of T2T. The most common reasons of failed treatment target were inability to escalate DMARDs due to side effects (18.8%), lack of biologics fund (15.6%), and persistent disease despite optimum treatment (14.1%). T2T was successfully implemented. Malay patients need aggressive treatment adaptation to achieve optimal outcome.

Entities:  

Keywords:  Clinical; Outcome; Rheumatoid arthritis; Routine; Treat-to-target

Mesh:

Substances:

Year:  2017        PMID: 28389855     DOI: 10.1007/s00296-017-3705-6

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  35 in total

1.  2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.

Authors:  Daniel Aletaha; Tuhina Neogi; Alan J Silman; Julia Funovits; David T Felson; Clifton O Bingham; Neal S Birnbaum; Gerd R Burmester; Vivian P Bykerk; Marc D Cohen; Bernard Combe; Karen H Costenbader; Maxime Dougados; Paul Emery; Gianfranco Ferraccioli; Johanna M W Hazes; Kathryn Hobbs; Tom W J Huizinga; Arthur Kavanaugh; Jonathan Kay; Tore K Kvien; Timothy Laing; Philip Mease; Henri A Ménard; Larry W Moreland; Raymond L Naden; Theodore Pincus; Josef S Smolen; Ewa Stanislawska-Biernat; Deborah Symmons; Paul P Tak; Katherine S Upchurch; Jirí Vencovsky; Frederick Wolfe; Gillian Hawker
Journal:  Ann Rheum Dis       Date:  2010-09       Impact factor: 19.103

2.  Impact of tight control strategy on rheumatoid arthritis in Sarawak.

Authors:  Cheng Lay Teh; Jin Shyan Wong
Journal:  Clin Rheumatol       Date:  2010-10-01       Impact factor: 2.980

3.  HLA-DRB1 genes and susceptibility to rheumatoid arthritis in three ethnic groups from Malaysia.

Authors:  K F Kong; S S Yeap; S K Chow; Maude E Phipps
Journal:  Autoimmunity       Date:  2002-07       Impact factor: 2.815

4.  Racial and ethnic disparities in disease activity and function among persons with rheumatoid arthritis from university-affiliated clinics.

Authors:  J L Barton; L Trupin; D Schillinger; S A Gansky; C Tonner; M Margaretten; V Chernitskiy; J Graf; J Imboden; E Yelin
Journal:  Arthritis Care Res (Hoboken)       Date:  2011-09       Impact factor: 4.794

Review 5.  Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice.

Authors:  Jaclyn Anderson; Liron Caplan; Jinoos Yazdany; Mark L Robbins; Tuhina Neogi; Kaleb Michaud; Kenneth G Saag; James R O'Dell; Salahuddin Kazi
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-05       Impact factor: 4.794

Review 6.  Impact of Obesity on Remission and Disease Activity in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis.

Authors:  Yang Liu; Glen S Hazlewood; Gilaad G Kaplan; Bertus Eksteen; Cheryl Barnabe
Journal:  Arthritis Care Res (Hoboken)       Date:  2016-12-31       Impact factor: 4.794

7.  Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial.

Authors:  Catriona Grigor; Hilary Capell; Anne Stirling; Alex D McMahon; Peter Lock; Ramsay Vallance; Wilma Kincaid; Duncan Porter
Journal:  Lancet       Date:  2004 Jul 17-23       Impact factor: 79.321

8.  Smoking interacts with HLA-DRB1 shared epitope in the development of anti-citrullinated protein antibody-positive rheumatoid arthritis: results from the Malaysian Epidemiological Investigation of Rheumatoid Arthritis (MyEIRA).

Authors:  Chun Lai Too; Abqariyah Yahya; Shahnaz Murad; Jasbir Singh Dhaliwal; Per Tobias Larsson; Nor Asiah Muhamad; Nor Aini Abdullah; Amal Nasir Mustafa; Lars Klareskog; Lars Alfredsson; Leonid Padyukov; Camilla Bengtsson
Journal:  Arthritis Res Ther       Date:  2012-04-26       Impact factor: 5.156

Review 9.  Evidence for treating rheumatoid arthritis to target: results of a systematic literature search.

Authors:  Monika Schoels; Rachel Knevel; Daniel Aletaha; Johannes W J Bijlsma; Ferdinand C Breedveld; Dimitrios T Boumpas; Gerd Burmester; Bernard Combe; Maurizio Cutolo; Maxime Dougados; Paul Emery; Desirée van der Heijde; Tom W J Huizinga; Joachim Kalden; Edward C Keystone; Tore K Kvien; Emilio Martin-Mola; Carlomaurizio Montecucco; Maarten de Wit; Josef S Smolen
Journal:  Ann Rheum Dis       Date:  2010-04       Impact factor: 19.103

10.  Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score.

Authors:  Daniel Aletaha; Valerie P K Nell; Tanja Stamm; Martin Uffmann; Stephan Pflugbeil; Klaus Machold; Josef S Smolen
Journal:  Arthritis Res Ther       Date:  2005-04-07       Impact factor: 5.156

View more
  6 in total

1.  Treat-to-target concept implementation for evaluating rheumatoid arthritis patients in daily practice.

Authors:  Tal Gazitt; Shirley Oren; Tatiana Reitblat; Merav Lidar; Alexandra Balbir Gurman; Itzhak Rosner; Nimer Halabe; Joy Feld; Sameer Kassem; Idit Lavi; Ori Elkayam; Devy Zisman
Journal:  Eur J Rheumatol       Date:  2019-05-20

2.  Crying out for equity: outcomes of rheumatic diseases confounded by ethnicity.

Authors:  Shirish Dubey; Adewale O Adebajo
Journal:  Clin Rheumatol       Date:  2022-07-19       Impact factor: 3.650

3.  A comprehensive care program achieves high remission rates in rheumatoid arthritis in a middle-income setting. Experience of a Center of Excellence in Colombia.

Authors:  Pedro Santos-Moreno; Nelson J Alvis-Zakzuk; Laura Villarreal-Peralta; Maria Carrasquilla-Sotomayor; Angel Paternina-Caicedo; Nelson Alvis-Guzmán
Journal:  Rheumatol Int       Date:  2017-12-16       Impact factor: 2.631

4.  Does healthcare regime affiliation influence the clinical outcomes of patients with rheumatoid arthritis?

Authors:  Julián E Barahona-Correa; Jorge Flórez-Suárez; Paola Coral-Alvarado; Paul Méndez-Patarroyo; Gerardo Quintana-López
Journal:  Clin Rheumatol       Date:  2020-08-19       Impact factor: 2.980

5.  Treatment Mode Preferences in Rheumatoid Arthritis: Moving Toward Shared Decision-Making.

Authors:  Peter C Taylor; Neil Betteridge; T Michelle Brown; John Woolcott; Alan J Kivitz; Cristiano Zerbini; Diane Whalley; Oyebimpe Olayinka-Amao; Connie Chen; Palle Dahl; Dario Ponce de Leon; David Gruben; Lara Fallon
Journal:  Patient Prefer Adherence       Date:  2020-01-20       Impact factor: 2.711

6.  Knowledge of cardiovascular disease risk in rheumatoid arthritis patients before and after educational intervention from a Southeast Asia country: Malaysia.

Authors:  Boon Ching Teoh; Syed Azhar Syed Sulaiman; Bee Eng Tan
Journal:  Arch Rheumatol       Date:  2020-06-22       Impact factor: 1.472

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.